2026 Cellular Therapy Conference, Charlotte
Accreditation: 5.75 Nursing Contact Hours | 5.75 ABIM MOC II | 5.75 AMA PRA Category 1 Credit™ | 5.75 ACPE Pharmacy
Venue: Le Méridien Charlotte, 555 South McDowell Street, Charlotte, NC, 28204, United States
Official conference page for 2026 Cellular Therapy Conference, Charlotte. https://binaytara.org/projects/conferences/cellular-therapy-conference-charlotte
About 2026 Cellular Therapy Conference, Charlotte
Faculty and committee
Conference program and agenda
Agenda
Friday, July 24th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Earle Burgess, MD
08:20 AM - 08:35 AM
Tumor-Infiltrating Lymphocyte (TIL) Therapy and Lifileucel in Advanced Melanoma: From Trials to Clinical Practice – Theresa Medina, MD
08:35 AM - 08:50 AM
The Emerging Role of BiTE Therapy in the Management of SCLC – Daniel Ricardo Carrizosa, MD, MS
08:50 AM - 09:05 AM
Advancing Immunotherapy in Prostate Cancer: The Emerging Role of Cellular and Bispecific Therapies – Earle Burgess, MD
09:05 AM - 09:20 AM
Panel Discussion
Moderators:
Earle Burgess, MD
Panelists:
Theresa Medina, MD; Daniel Ricardo Carrizosa, MD, MS
Session Chair: Peter Voorhees, MD
09:30 AM - 09:40 AM
Update on BCMA-targeted T Cell Redirecting Therapy for Multiple Myeloma – Sascha Tuchman, MD
09:40 AM - 09:50 AM
Update on GPRC5D-targeted T Cell Redirecting Therapy for Multiple Myeloma – Susan Bal, MD
09:50 AM - 10:00 AM
Next Generation T Cell Redirecting Therapy for Multiple Myeloma – Cindy Varga, MD
10:00 AM - 10:10 AM
Choosing the Right T Cell Redirecting Therapy for Patients with Multiple Myeloma in Early Relapse – Peter Voorhees, MD
10:10 AM - 10:20 AM
Towards Outpatient Administration of T Cell Redirecting Therapies Multiple Myeloma – Chris Ferreri, MD
10:20 AM - 10:30 AM
Panel Discussion
Moderators:
Peter Voorhees, MD
Panelists:
Sascha Tuchman, MD; Susan Bal, MD; Cindy Varga, MD; Chris Ferreri, MD
Session Chair: Thomas Knight, MD
10:30 AM - 10:45 AM
CAR-T and Bispecifics for CLL – Debbie Stephens, DO
10:45 AM - 11:00 AM
CAR-T and Bispecifics for ALL – Thomas Knight, MD
11:00 AM - 11:15 AM
Maintenance After Transplant in Leukemia – Michael Richard Grunwald, MD
11:15 AM - 11:30 AM
Transplantation and Cellular Therapy in MPNs – Ben Vincent, MD
11:30 AM - 11:45 AM
Panel Discussion
Moderators:
Thomas Knight, MD
Panelists:
Ben Vincent, MD; Michael Richard Grunwald, MD; Debbie Stephens, DO
Session Chair: Stefanie Sarantopulos, MD, PhD
12:45 PM - 01:00 PM
The Cord Blood Donor Option: Is it Really Only a Donor of Last Resort? – Sanghee Hong, MD
01:00 PM - 01:15 PM
Cyclophosphamide: A Major Advance, Data-Driven Considerations For Use – Paul Armistead, MD, PhD
01:15 PM - 01:30 PM
The Nuts and Bolts of Chronic GVHD Care and Long Term Care of Allo Act Patients – Stefanie Sarantopulos, MD, PhD
01:30 PM - 01:45 PM
FDA Approved Agents for GVHD – Joseph Pidala, MD, PhD
01:45 PM - 01:50 PM
Best practice use of agents – Elizabeth R. Eubanks, PharmD
01:50 PM - 02:00 PM
Panel Discussion
Moderators:
Stefanie Sarantopulos, MD, PhD
Panelists:
Sanghee Hong, MD; Paul Armistead, MD, PhD; Joseph Pidala, MD, PhD; Elizabeth R. Eubanks, PharmD
Session Chair: Natalie S Grover, MD
02:00 PM - 02:15 PM
Bispecifics for DLBCL – Mary Beth Seegars, MD
02:15 PM - 02:30 PM
CAR-T for DLBCL – Chenyu Lin, MD
02:30 PM - 02:45 PM
CAR-T and Bispecifics for Indolent Lymphomas – Alan Skarbnik, MD
02:45 PM - 03:00 PM
CAR-T for Mantle Cell Lymphoma – Nilanjan Ghosh, MD, PhD
03:00 PM - 03:05 PM
Case Presentation – Brandon Tedder, MD
03:05 PM - 03:15 PM
Case-Based Discussion
Moderators:
Natalie S Grover, MD
Panelists:
Mary Beth Seegars, MD; Chenyu Lin, MD; Alan Skarbnik, MD; Nilanjan Ghosh, MD, PhD; Brandon Tedder, MD
Venue and map
Accreditations and continuing education
Acknowledgement of Commercial Support
This activity is supported with an Independent Medical Education grant from Amgen.